Analysis The Lipid Change Of Non-dialysis Patients With Chronic Renal Failure

Currently, the treatment of CRF is still majorly treat the primary disease, avoiding factors which can aggravate to damage kidney, and other eliminating symptom. The factors which aggravate renal failure such as hypertension, proteinuria, hyperglycemia and other factors have been emphasized for a long time, but the damage of hyperlipemia to the kidney is often ignored by clinicians. The damage to kidney of hyperlipidemia is insidious, piecemeal and progressive, it may cause mesangial cell proliferation, extracellular matrix accumulation, endothelial cell dysfunction and injury, and it can lead to renal atherosclerosis and accelerate renal failure.The patients with CRF usually combine with abnormal lipid metabolism, the paper observed the change of lipid in patients of non-dialysis with CRF to discussion the relationship between the damage of renal function and lipid metabolism disorder, and to the explore the necessity of hyperlipemia therapy.In this paper, 50 second clinical hospital cases of non-dialysis patients with CRF were collected, all patients have no history of coronary heart disease and liver disease. Another clinical observation of 80 cases of CRF in patients with hyperlipidemia, according to the treatment and control groups were divided randomly into two groups , which are no significant statistical difference in sex, average age, average length of stay, primary disease, and so on. Statistics collected 50 cases of patients were hospitalized with first and second serum TG, TC, TG, ApoB, HDL-c, TP, ALB, CRE. Clinical observation patients of 80 cases draw blood samples from fasting in the morning before and after treatment, to measure their serum TG, TC, HDL, CRE, BUN and 24-hour urine protein levels by Hitachi Hitachi7150 automatic biochemical analyzer. We should monitor the level of serum CRE and TC in the course of treatment, when TC<3.0mmol/l or CRE>450umol/l fluvastatin should be suspended, other treatment such as low-protein diet, lower blood pressure, promotting toxin discharge, correcting anemia, correcting acid-base balance are basically conventional. 40 patients of treatment group take orally fluvastatin(Novartis pharmaceutical production) 20mg each morning and evening since the first hospitalization, and the control group was not taking other lipid-lowering drugs. Measurement data were used several±standard deviation (±s). Clinical collected cases of 50 cases, Fluvastatin treatment of 40 cases and 40 control group patients according to the indicators were paired t test twice before and after hospitalization and treatment, P <0.05 for the difference was significant.The result indicate:1.The result of 50 clinical collection cases showed that with the extended duration and the increasing CRF, the second hospitalization cases of hyperlipidemia increased 24% than the initial hospitalization, in which the cases of simply hypertriglyceridemia increased 20%. The serum level of TC, TG, ApoB obviously higher than the initial hospitalization, and TG (P <0.001) increased more notable. ApoA1,HDL-c,TP and ALB obviously lower than the initial hospitalization,and CRE increased obviously. All that have statistical significance.2. 40 patients Combined with hyperlipidemia with CRF in the fluvastatin treatment group showed no obvious adverse reactions in the course of treatment, and CRE>450umol/l or TC<3.0mmol/l cases didn't emerge. The level of serum TG , TC decreased obviously after the fluvastatin treatment. Serum CRE, BUN and 24-hour urine protein were obviously lower, and HDL-c increased obviously. All that have statistically significant.3. 40 patients combined with hyperlipidemia with CRF in the control group showed that the level of TG, TC increased significantly after conventional treatment; The level of serum HDL-c , CRE , BUN and 24-hour urine protein was significantly decreased. All that have statistical significance.4. Compare fluvastatin treatment group with the control group: The level of serum TG, TC decreased obviously after fluvastatin treatment, and HDL-c increased obviously. While the level of serum TG, TC of control group increased obviously, and HDL-c obviously lower. All that have statistical significance, but blood CRE, BUN and 24-hour urine protein of the treatment group decreased more notably.We can draw such conclusions from this study: With increasing duration of the extension and degree of renal failure, the patient with CRF increased lipid metabolism disorders. Application of fluvastatin to treat patients with CRF associated with hyperlipidemia, in addition to offset the abnormal blood lipid changes, could still play important role of lipid lowering, decrease urine protein and protection kidney and renal function delay. Monitoring serum lipids, controlling blood lipids and lipid-lowering necessarily therapy for the protection of residual renal function is very important.